Analysis of camelid IgG for antivenom development: Immunoreactivity and preclinical neutralisation of venom-induced pathology by IgG subclasses, and the effect of heat treatment

Toxicon

Volumn 56, Issue 4, 2010, Pages 596-603

  Cook, Darren A N ^a   Samarasekara, Chamali L ^a   Wagstaff, Simon C ^a   Kinne, Joerg ^b   Wernery, Ulrich ^b   Harrison, Robert A ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b CENTRAL VETERINARY RESEARCH LABORATORY   (United Arab Emirates)

Author keywords

Camelid IgG; Echis ocellatus; Heavy chain IgG; Snake antivenom; Venom

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; SNAKE VENOM ANTISERUM;

ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; ARTIODACTYLA; BINDING AFFINITY; BLEEDING; BLOOD CLOTTING DISORDER; CAMEL; CHROMATOGRAPHY; CONTROLLED STUDY; ECHIS OCELLATUS; ENVENOMATION; FEMALE; HEAT TREATMENT; IMMUNIZATION; IMMUNOREACTIVITY; MALE; NONHUMAN; POISONOUS SNAKE; PRIORITY JOURNAL; SEPARATION TECHNIQUE;

CAMELIDAE; ECHIS OCELLATUS; EQUIDAE; OVIS; OVIS ARIES;

EID: 77955014031     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2010.06.004     Document Type: Article

References (36)

1. Aghaie A., Pourfathollah A.A., Bathaie S.Z., Moazzeni S.M., Khorsand Mohammad Pour H., Banazadeh S. Structural study on immunoglobulin G solution after pasteurization with and without stabilizer. Transfusion Medicine 2008, 18(1):62-70.
2. Burnouf T., Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Reviews 2000, 14(2):94-110.
3. Chandra S., Groener A., Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thrombosis Research 2002, 105(5):391-400.
4. Chinonavanig L., Billings P.B., Matangkasombut P., Ratanabanangkoon K. Antigenic relationships and relative immunogenicities of venom proteins from six poisonous snakes of Thailand. Toxicon 1988, 26(9):883-890.
5. Cook D.A.N., Owen T., Wagstaff S.C., Kinne J., Wernery U., Harrison R.A. Analysis of camelid IgG for antivenom development: serological responses of venom-immunised camels to prepare either monospecific or polyspecific antivenoms for West Africa. Toxicon 2010, 56(3):363-372.
6. Cook D.A.N., Owen T., Wagstaff S.C., Kinne J., Wernery U., Harrison R.A. Analysis of camelid antibodies for antivenom development: neutralisation of venom-induced pathology. Toxicon 2010, 56(3):373-380.
7. Daley L.P., Gagliardo L.F., Duffy M.S., Smith M.C., Appleton J.A. Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new world camelids. Clinical and Diagnostic Laboratory Immunology 2005, 12(3):380-386.
8. De Genst E., Silence K., Decanniere K., Conrath K., Loris R., Kinne J., Muyldermans S., Wyns L. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(12):4586-4591.
9. Fernandez G.P., Segura A., Herrera M., Velasco W., Solano G., Gutierrez J.M., Leon G. Neutralization of Bothrops mattogrossensis snake venom from Bolivia: experimental evaluation of llama and donkey antivenoms produced by caprylic acid precipitation. Toxicon 2010, 55(2-3):642-645.
10. Goldman E.R., Anderson G.P., Conway J., Sherwood L.J., Feen M., Vo B., Liu J.L., Hayhurst A. Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex. Analytical Chemistry 2008, 80(22):8583-8591.
11. Gutierrez J.M., Fan H.W., Silvera C.L.M., Angulo Y. Stability, distribution and use of antivenoms for snakebite envenomation in Latin America: report of a workshop. Toxicon 2009, 53(6):625-630.
12. Gutierrez J.M., Gondo Higashi H., Hui Wen F., Burnouf T. Strengthening antivenom production in Central and South American public laboratories: report of a workshop. Toxicon 2007, 49(1):30-35.
13. Gutierrez J.M., Theakston R.D.G., Warrell D.A. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Medicine 2006, 3(6):727-731.
14. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. Naturally-occurring antibodies devoid of light-chains. Nature 1993, 363(6428):446-448.
15. Harrison R.A., Hasson S.S., Harmsen M., Laing G.D., Conrath K., Theakston R.D.G. Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. Toxicon 2006, 47(3):364-368.
16. Harrison R.A., Hargreaves A., Wagstaff S.C., Faragher B., Lalloo D.G. Snake envenoming: a disease of poverty. PLoS Neglected Tropical Diseases 2009, 3(12):e569.
17. Harrison R.A., Wernery U. The unique properties of camelid IgG have potential to improve the treatment of snake bite. Journal of Camel Practice and Research 2007, 14(1):15-16.
18. Herrera M., Leon G., Segura A., Meneses F., Lomonte B., Chippaux J.P., Gutierrez J.M. Factors associated with adverse reactions induced by caprylic acid-fractionated whole IgG preparations: comparison between horse, sheep and camel IgGs. Toxicon 2005, 46(7):775-781.
19. Hilfenhaus J., Weidmann E. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates. Arzneimittel-Forschung 1986, 36(4):621-625.
20. Kasturiratne A., Wickremasinghe A.R., de Silva N., Gunawardena N.K., Pathmeswaran A., Premaratna R., Savioli L., Lalloo D.G., de Silva H.J. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Medicine 2008, 5(11):1591-1604.
21. Lauwereys M., Ghahroudi M.A., Desmyter A., Kinne J., Holzer W., De Genst E., Wyns L., Muyldermans S. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO Journal 1998, 17(13):3512-3520.
22. Mannucci P.M. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sanguinis 1993, 64(4):197-203.
23. Meddeb-Mouelhi F., Bouhaouala-Zahar B., Benlasfar Z., Hammadi M., Mejri T., Moslah M., Karoui H., Khorchani T., El Ayeb M. Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins. Toxicon 2003, 42(7):785-791.
24. Mpandi M., Schmutz P., Legrand E., Duc R., Geinoz J., Henzelin-Nkubana C., Giorgia S., Clerc O., Genoud D., Weber T. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins. Biologicals 2007, 35(4):335-341.
25. Nowak T., Niedrig M., Bernhardt D., Hilfenhaus J. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation. Developments in Biological Standardization 1993, 81:169-176.
26. Omidfar K., Rasaee M.J., Kashanian S., Paknejad M., Bathaie Z. Studies of thermostability in Camelus bactrianus (Bactrian camel) single-domain antibody specific for the mutant epidermal-growth-factor receptor expressed by Pichia. Biotechnology and Applied Biochemistry 2007, 46:41-49.
27. Otero R., León G., Gutiérrez J.M., Rojas G., Toro M.F., Barona J., Rodríguez V., Díaz A., Núñez V., Quintana J.C., Ayala S., Mosquera D., Conrado L.L., Fernández D., Arroyo Y., Paniagua C.A., López M., Ospina C.E., Alzate C., Fernández J., Meza J.J., Silva J.F., Ramírez P., Fabra P.E., Ramírez E., Córdoba E., Arrieta A.B., Warrell D.A., Theakston R.D.G. Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without [beta]-propiolactone, in the treatment of Bothrops asper bites in Colombia. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006, 100(12):1173-1182.
28. Pratanaphon R., Akesowan S., Khow O., Sriprapat S., Ratanabanangkoon K. Production of highly potent horse antivenom against the Thai cobra (Naja kaouthia). Vaccine 1997, 15(14):1523-1528.
29. Rojas G., Jimenez J., Gutierrez J.M. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon 1994, 32(3):351-363.
30. Steinbuch M., Audran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Archives of Biochemistry and Biophysics 1969, 134(2):279-284.
31. Theakston R.D.G., Reid H.A. Development of simple standard assay procedures for the characterization of snake venoms. Bulletin of the World Health Organization 1983, 61(6):949-956.
32. Theakston R.D.G., Warrell D.A. Crisis in snake antivenom supply for Africa. Lancet 2000, 356(9247). 2104.
33. van der Linden R.H.J., Frenken L.G.J., de Geus B., Harmsen M.M., Ruuls R.C., Stok W., de Ron L., Wilson S., Davis P., Verrips C.T. Comparison of physical chemical properties of llama V-HH antibody fragments and mouse monoclonal antibodies. Biochimica Et Biophysica Acta - Protein Structure and Molecular Enzymology 1999, 1431(1):37-46.
34. Williams D., Gutierrez J.M., Harrison R., Warrell D.A., White J., Winkel K.D. Viewpoint: an antidote for snake bite. The global snake bite initiative. Lancet 2010, 375:89-91.
35. WHO http://www.who.int/neglected_diseases/diseases/snakebites/en/index.html.
36. WHO Guidelines for the Production, Control and Regulation of Snake Antivenom Immnoglobulins 2010, World Health Organisation, Geneva.